This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EU Agencies Doubtful About Need for 2nd COVID Booster
by Kinjel Shah
The European health agencies agreed that the fourth dose of mRNA-based COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) may be given to adults 80 years and above.
Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids
by Zacks Equity Research
Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.
Company News for Mar 31, 2022
by Zacks Equity Research
Companies In The News Are: FIVE, MSM, BNTX, AER.
FDA Authorizes Pfizer, Moderna's Second COVID Booster Dose
by Kinjel Shah
The FDA authorized a second booster dose of COVID-19 vaccines made by Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for older adults and some immunocompromised individuals.
Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.
Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Target Hospitality and Big Lots have been highlighted as Zacks Bull and Bear of the Day
Pfizer (PFE) Recalls Hypertension Drug Due to Impurities
by Zacks Equity Research
Pfizer (PFE) is recalling six lots of Accuretic tablets, one lot of quinapril and hydrochlorothiazide tablets and four lots of quinapril HCl/ hydrochlorothiazide tablets.
FDA Panel to Discuss Fourth Booster Dose in April Meeting
by Kinjel Shah
The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.
Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab
by Zacks Equity Research
Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.
The Zacks Analyst Blog Highlights J&J, Pfizer, BioNTech, and Moderna
by Zacks Equity Research
J&J, Pfizer, BioNTech, and Moderna have been highlighted in this Analyst Blog.
What's in Store for J&J's (JNJ) Segments & Pipeline in 2022?
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above market levels. The Consumer unit is improving. The Medical Devices unit is being hurt by soft recovery trends in medical procedures.
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $165, moving +0.66% from the previous trading session.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.
BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) fourth-quarter earnings call, investors' focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.
Moderna (MRNA) Starts Omicron-Specific Bivalent Booster Study
by Zacks Equity Research
Moderna (MRNA) administers the first dose in the phase II study of its Omicron-specific bivalent booster candidate (mRNA-1273.214). It expects to enrol 375 subjects for the same in the United States.
The Zacks Analyst Blog Highlights Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences
by Zacks Equity Research
Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.
Pfizer (PFE) Begins Pediatric Study on COVID Pill Paxlovid
by Zacks Equity Research
Pfizer's (PFE) Paxlovid is the first oral antiviral pill to be studied in a pediatric clinical study.
Biotech Stock Roundup: OCGN Down on Update, VYGR Surges on Deal & Other Updates
by Zacks Equity Research
Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
by Zacks Equity Research
BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $128.16, moving +1.51% from the previous trading session.
Ocugen (OCGN) Down 23% With FDA Denial of COVID Vaccine EUA
by Zacks Equity Research
The FDA turns down an emergency use authorization request from Ocugen (OCGN) to use its COVID-19 vaccine Covaxin in pediatric population. Stock depreciates.
Novavax's (NVAX) Q4 Loss Wider Than Expected, 2022 View Weak
by Zacks Equity Research
Novavax (NVAX) reports a wider-than-expected loss for the fourth quarter of 2021. Also, revenues miss estimates. Its shares decline in after-market trading following the announcement.
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $150.81, moving +0.13% from the previous trading session.